Adamas Pharmaceuticals Inc (OQ:ADMS)

Business Focus: Biotechnology & Medical Research

Sep 11, 2020 04:04 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 269,250 shares of the company’s common stock, at a per...
Sep 11, 2020 09:15 am ET
Adamas presents new post-hoc data analysis for GOCOVRI® in Parkinson’s disease patients with dyskinesia at the 2020 Movement Disorder Society Virtual Congress
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI® (amantadine)...
Sep 08, 2020 04:05 pm ET
Adamas to Present at Upcoming HC Wainwright Conference
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief...
Sep 01, 2020 09:15 am ET
Adamas Appoints Anna Richo to Board of Directors
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the appointment of Anna Richo, J.D., General...
Aug 14, 2020 04:04 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 36,000 shares of the company’s common stock, at a per...
Aug 06, 2020 04:02 pm ET
Adamas Reports Second Quarter 2020 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the second quarter ended...
Jul 23, 2020 04:02 pm ET
Adamas to Announce Second Quarter 2020 Financial Results and Host Conference Call on August 6, 2020
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 second quarter financial results on Thursday, August 6, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...
Jul 15, 2020 08:00 am ET
Adamas presents new post-hoc Phase 3 data analysis for GOCOVRI® in Parkinson’s disease at the 2020 American Academy of Neurology (AAN) Science Highlights Platform
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced its presentation of a new post-hoc pivotal trial...
Jul 10, 2020 04:05 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 62,500 shares of the company’s common stock, at a per...
Jun 17, 2020 04:01 pm ET
Adamas provides program update for ADS-5102 for multiple sclerosis patients with walking impairment
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the completion of its evaluation of ADS-5102 in...
Jun 04, 2020 04:30 pm ET
Adamas announces FDA filing acceptance of sNDA to modify the indication statement for GOCOVRI® to include treatment for Parkinson’s disease patients receiving levodopa and experiencing OFF episodes
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that its supplemental New Drug Application (sNDA)...
Jun 03, 2020 04:01 pm ET
Adamas to Present at Upcoming William Blair Conference
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s...
May 13, 2020 09:15 am ET
Adamas announces issuance of new U.S. patent for GOCOVRI in Parkinson’s disease - expands coverage with reduction of ‘OFF’ time and increased ‘good ON’ time
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has been issued a new patent (no. 10,646,456)...
May 08, 2020 06:46 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 66,000 shares of the company’s common stock, at a per...
May 07, 2020 04:03 pm ET
Adamas Reports First Quarter 2020 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today reported financial results for the first quarter ended...
Apr 27, 2020 04:03 pm ET
Adamas to Announce First Quarter 2020 Financial Results and Host Conference Call on May 7, 2020
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...
Apr 10, 2020 04:06 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees the option to purchase an aggregate of 86,000 shares of the company’s common stock, at a per...
Mar 23, 2020 03:15 pm ET
Adamas Pharmaceuticals Stock – Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors – ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals, Inc. On March 16, 2020, a verified...
Mar 19, 2020 04:46 pm ET
Adamas Pharmaceuticals Stock - Kehoe Law Firm, P.C. Investigating Breach of Fiduciary Duty Claims on Behalf of ADMS Investors - ADMS Shareholders Encouraged to Contact Kehoe Law Firm, P.C.
PHILADELPHIA, March 19, 2020 /PRNewswire/ -- Kehoe Law Firm, P.C. is investigating breach of fiduciary duty claims on behalf of shareholders of Adamas Pharmaceuticals, Inc. (NasdaqGM: ADMS) that presently own the common stock of Adamas Pharmaceuticals, Inc....
Mar 06, 2020 04:39 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 70,000 shares of the company’s common stock, at a per...
Feb 25, 2020 04:03 pm ET
Adamas Reports Fourth Quarter and Full Year 2019 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today reported financial results for the fourth...
Feb 20, 2020 04:01 pm ET
Adamas to Present at Upcoming Healthcare Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s...
Feb 19, 2020 04:02 pm ET
Adamas to Announce Fourth Quarter 2019 Financial Results and Host Conference Call on February 25, 2020
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 fourth quarter financial results on Tuesday, February 25, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and...
Feb 13, 2020 09:00 am ET
Adamas To Present Analysis of Clinical Trials on GOCOVRI® Treatment at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, announced today two presentations on GOCOVRI®...
Feb 11, 2020 04:15 pm ET
Adamas Announces Publication of the Two-Year Phase 3 Open-Label EASE LID 2 Trial of GOCOVRI® for Dyskinesia in Patients with Parkinson’s Disease
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) a company dedicated to developing and delivering medicines that make a clinically meaningful difference for people affected by neurological diseases, today announced the publication of final results from...
Feb 10, 2020 10:00 am ET
ADMS FINAL DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”), of the important February 10, 2020...
Feb 07, 2020 10:00 am ET
DEADLINE ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adamas Pharmaceuticals, Inc. (“Adamas” or the Company”) (NASDAQ: ADMS) and certain of its officers, on behalf of...
Feb 05, 2020 11:26 am ET
ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS). If you purchased Adamas stock pursuant to the Company’s January 24, 2018...
Feb 04, 2020 01:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Feb 04, 2020 12:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Feb 04, 2020 11:12 am ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Feb 03, 2020 01:00 pm ET
DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Feb 03, 2020 10:11 am ET
ADMS INVESTOR DEADLINE IN 7 DAYS: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Against Adamas Pharmaceuticals, Inc.
Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action filed on behalf of investors that purchased or acquired the securities of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) between August 8, 2017, and September 30, 2019, inclusive (the “Class Period”). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exchange Act of 1934.
Feb 01, 2020 02:00 pm ET
ADMS FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”), of the important February 10, 2020...
Jan 31, 2020 02:22 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Jan 31, 2020 01:37 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 31, 2020 11:16 am ET
ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:ADMS) of the February 10, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Jan 29, 2020 01:19 pm ET
ADAMAS DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc. (ADMS) To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:ADMS) of the February 10, 2020 deadline to seek the role of lead plaintiff in a federal securities...
Jan 29, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Jan 29, 2020 09:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against X Financial, Baozun, Adamas Pharmaceuticals, and Cintas and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of X Financial (NYSE: XYF), Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals,...
Jan 28, 2020 10:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 27, 2020 05:06 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Jan 27, 2020 11:00 am ET
DEADLINE ALERT for XYF, BZUN, ADMS, MHK: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 24, 2020 10:00 am ET
INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 23, 2020 05:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 23, 2020 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Jan 22, 2020 02:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS),...
Jan 22, 2020 01:19 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Jan 21, 2020 05:50 pm ET
ADMS INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”), of the important February 10, 2020...
Jan 21, 2020 11:00 am ET
DEADLINE ALERT for HEXO, XYF, BZUN, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 17, 2020 12:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 16, 2020 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Jan 15, 2020 04:32 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Baozun, Adamas Pharmaceuticals, Cintas, and Correvio Pharma and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Baozun, Inc. (NASDAQ: BZUN), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS),...
Jan 14, 2020 04:02 pm ET
ROSEN, A LEADING LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”), of the important February 10, 2020...
Jan 13, 2020 01:13 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Jan 13, 2020 11:00 am ET
DEADLINE ALERT for HEXO, XYF, ADMS, EXC: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 10, 2020 04:30 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 12,000 shares of the company’s common stock, at a per...
Jan 10, 2020 11:00 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Jan 10, 2020 10:00 am ET
INVESTOR ALERT: ADMS and BZUN: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders With Losses Exceeding $100K of Class Action Deadlines
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jan 09, 2020 03:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Adamas Pharmaceuticals, Cintas, Correvio Pharma, and Exelon and Encourages Investors to Contact the Fir
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of  Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), Cintas Corporation (NASDAQ:...
Jan 09, 2020 08:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
NEW YORK, Jan. 9, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company") (NASDAQ:  ADMS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jan 08, 2020 12:24 pm ET
INVESTOR CLASS ACTION DEADLINES: Bernstein Liebhard LLP Reminds Investors in Adamas Pharmaceuticals, and Exelon Corporation of Filing Deadlines
Bernstein Liebhard LLP announces that class action complaints have been filed on behalf of shareholders of ADMS and EXC. If you wish to serve as lead plaintiff, you must move the court by the lead plaintiff deadlines listed below. A lead plaintiff...
Jan 08, 2020 09:15 am ET
Adamas Provides Preliminary Fourth Quarter and Full Year 2019 GOCOVRI® Product Sales and Outlines Key Priorities for 2020
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today provides preliminary unaudited fourth quarter...
Jan 06, 2020 01:00 pm ET
DEADLINE ALERT for YJ, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion....
Jan 06, 2020 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 04, 2020 11:00 am ET
ADMS INVESTOR ALERT: ROSEN, A TOP LAW FIRM, Reminds Adamas Pharmaceuticals, Inc. Investors of Important February 10th Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”) of the important February 10, 2020...
Jan 03, 2020 06:54 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jan 03, 2020 11:30 am ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Jan 02, 2020 12:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Net 1 UEPS Technologies, X Financial, Baozun, and Adamas Pharmaceuticals and Encourages Investors to Co
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Net 1 UEPS Technologies, Inc. (NASDAQ: UEPS), X Financial (NYSE: XYF), Baozun,...
Jan 02, 2020 09:00 am ET
Adamas Announces Settlement of Patent Litigation with Sandoz Inc.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that it has entered into a Settlement...
Dec 31, 2019 02:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Dec 30, 2019 12:30 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS)...
Dec 27, 2019 11:47 am ET
ROSEN, NATIONAL TRIAL LAWYERS, Reminds Adamas Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action – ADMS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”) of the important February 10, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Adamas investors under the federal securities laws.
Dec 23, 2019 05:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Dec 23, 2019 12:00 pm ET
DEADLINE ALERT for UNIT, UEPS, XYF, ADMS: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders
Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....
Dec 20, 2019 12:00 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:
Dec 20, 2019 10:00 am ET
SHAREHOLDER ALERT - Adamas Pharmaceuticals, Inc. (ADMS) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: February 10, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Adamas Pharmaceuticals, Inc. (“Adamas” or the Company”) (Nasdaq: ADMS) and certain of its officers, on behalf of...
Dec 19, 2019 07:12 pm ET
EQUITY ALERT: ROSEN LAW FIRM Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. – ADMS
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the...
Dec 18, 2019 12:00 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Adamas Pharmaceuticals, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming February 10, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) securities between August 8, 2017 and September 30, 2019, inclusiv
Dec 17, 2019 06:18 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:
Dec 17, 2019 04:41 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:  ADMS)  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Dec 17, 2019 09:00 am ET
Adamas Announces Top-Line Results from INROADS Phase 3 Trial of ADS-5102 for Multiple Sclerosis Patients with Walking Impairment
Dose-response observed for both efficacy and safety - - Safety data consistent with known safety profile of amantadine - EMERYVILLE, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to...
Dec 13, 2019 04:00 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceuticals, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ:
Dec 13, 2019 01:36 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Adamas Pharmaceuticals, Inc. Investors
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) securities between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”). Adamas investors have until February 10, 2020
Dec 12, 2019 08:43 pm ET
Shareholder Alert: Robbins LLP Announces Adamas Pharmaceuticals, Inc. (ADMS) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between August 8, 2017 and September 30, 2019. Adamas is a commercial stage pharmaceutical company that specializes in dev
Dec 12, 2019 08:00 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) investors concerning the Company and its officers’ possible violations of federal securities laws.
Dec 12, 2019 06:19 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Adamas Pharmaceuticals, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS) investors concerning the Company and its officers’ possible violations of federal securities laws.
Dec 12, 2019 01:02 pm ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:
Dec 11, 2019 05:46 pm ET
ADMS LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. – ADMS
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) between August 8, 2017 and September 30, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Adamas investors under the federal securities laws.
Dec 11, 2019 04:16 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Has Filed a Class Action Lawsuit Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, has filed a class action lawsuit against Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:
Dec 09, 2019 04:50 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 89,000 shares of the company’s common stock, at a per...
Nov 21, 2019 04:02 pm ET
Adamas to Present at Upcoming Evercore ISI and Piper Jaffray Investor Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is...
Nov 08, 2019 04:01 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 14,500 shares of the company’s common stock, at a per...
Nov 07, 2019 04:03 pm ET
Adamas Reports Third Quarter 2019 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the third quarter ended September 30, 2019,...
Oct 30, 2019 04:30 pm ET
Adamas to Announce Third Quarter 2019 Financial Results and Host Conference Call on November 7, 2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 third quarter financial results on Thursday, November 7, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and...
Oct 08, 2019 04:03 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 44,375 shares of the company’s common stock, at a per...
Sep 27, 2019 04:05 pm ET
Adamas to Present at Upcoming Cantor Fitzgerald Investor Conference
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is...
Sep 20, 2019 08:00 am ET
Adamas Announces New Safety and Efficacy Data for GOCOVRI® in Parkinson’s Disease Patients with Dyskinesia at the Movement Disorder Society 2019 International Congress
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, announced today the presentation of new data on GOCOVRI® (amantadine) extended...
Sep 17, 2019 04:15 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted its new Chief Executive Officer, Neil F. McFarlane, the option to purchase an aggregate of 250,000 shares of the...
Sep 13, 2019 07:30 am ET
Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Neil McFarlane has been named Chief Executive Officer and...
Sep 10, 2019 04:15 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 17,250 shares of the company’s common stock, at a per...
Aug 12, 2019 05:07 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 5,000 shares of the company’s common stock, at a per...
Aug 08, 2019 04:02 pm ET
Adamas Reports Second Quarter 2019 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2019, as...
Jul 23, 2019 04:05 pm ET
Adamas to Announce Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 second quarter financial results on Thursday, August 8, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and...
Jul 16, 2019 05:03 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM: ADMS) concerning possible violations of federal securities laws. According to a recently filed...
Jul 08, 2019 04:29 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 11,000 shares of the company’s common stock, at a per...
Jun 18, 2019 04:05 pm ET
Adamas Announces Publication and Presentation of a Data Analysis Demonstrating GOCOVRI Reduces Both the Frequency and Duration of Daily Episodes of Troublesome Dyskinesia and OFF in Parkinson’s Diseas
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced a retrospective data analysis from pooled Phase 3 trials of...
Jun 17, 2019 05:54 pm ET
ADMS INVESTORS NOTICE: Lieff Cabraser Investigates Claims Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (Nasdaq: ADMS), including investors who purchased Adamas common stock directly in the Company’s January 24
Jun 17, 2019 05:23 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM: ADMS) concerning possible violations of federal securities laws. According to a recently filed...
Jun 12, 2019 07:05 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
Jun 10, 2019 09:00 am ET
ADMS INVESTORS ALERT: Lieff Cabraser Announces Securities Class Action Against Adamas Pharmaceuticals, Inc.
The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action litigation has been filed on behalf of investors who purchased the common stock of Ad
Jun 07, 2019 05:30 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 148,500  shares of the company’s common stock, at a...
Jun 04, 2019 11:49 am ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of...
Jun 03, 2019 04:31 pm ET
Adamas to Present at Upcoming JMP Investor Conference
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief...
May 31, 2019 11:45 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Fir
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ: ADMS) for violations of §§10(b) and 20(a) of...
May 30, 2019 07:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Adamas Pharmaceuticals, Inc. - ADMS
Pomerantz LLP is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or the “Company”) (NASDAQ: ADMS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext....
May 30, 2019 06:31 pm ET
ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.’s January 24, 2018 Secondary Public Offering To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS). If you purchased Adamas stock pursuant to the Company’s January 24, 2018...
May 30, 2019 04:30 pm ET
Adamas Pharmaceuticals Welcomes Vijay Shreedhar as Chief Commercial Officer 
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that Vijay Shreedhar, PhD, has joined the Company as its Chief...
May 29, 2019 10:32 am ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:
May 28, 2019 09:00 pm ET
Bragar Eagel & Squire, P.C. is Investigating Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on Behalf of Adamas Stockholders and Encourages Adamas Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) on behalf of Adamas stockholders.  Our investigation concerns whether Adamas has violated the federal securities laws and/or engaged...
May 28, 2019 05:55 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
Levi & Korsinsky reminds investors that it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM: ADMS) concerning possible violations of federal securities laws. According to a recently filed...
May 28, 2019 03:58 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Adamas Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQ:
May 28, 2019 02:28 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Adamas Pharmaceuticals, Inc. – ADMS
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) resulting from allegations that Adamas may have issued materially misleading business information to the investing public.
May 24, 2019 08:17 pm ET
ADAMAS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Adamas Pharmaceuticals, Inc.'s January 24, 2018 Secondary Public Offering To Contact The Firm
NEW YORK, May 24, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Adamas Pharmaceuticals, Inc. ("Adamas" or the "Company")(NASDAQ:ADMS)....
May 24, 2019 04:08 pm ET
EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Adamas Pharmaceuticals, Inc.
Levi & Korsinsky announces it has commenced an investigation of Adamas Pharmaceuticals, Inc. (“Adamas” or “the Company”) (NASDAQGM: ADMS) concerning possible violations of federal securities laws. According to a recently filed complaint, before...
May 23, 2019 05:44 pm ET
Robbins Arroyo LLP: Complaint Alleges that Adamas Pharmaceuticals Inc. (ADMS) Misled Shareholders
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1933 pursuant to the company's January 2018 secondary public offering
May 13, 2019 11:14 am ET
Adamas to Present at Upcoming BAML Investor Conference
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief...
May 09, 2019 04:03 pm ET
Adamas Reports First Quarter 2019 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today reported financial results for the first quarter ended March 31, 2019, as...
May 06, 2019 09:39 pm ET
Adamas Announces Data Presentations at the 71st American Academy of Neurology Annual Meeting
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that posters regarding GOCOVRITM (amantadine) extended release...
May 02, 2019 04:05 pm ET
Adamas to Announce First Quarter 2019 Financial Results and Host Conference Call on May 9, 2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2019 first quarter financial results on Thursday, May 9, 2019, after market close. Subsequently, Adamas’ management team will host a conference call and...
Apr 03, 2019 07:55 am ET
Detailed Research: Economic Perspectives on KB Home, Fitbit, Adamas Pharmaceuticals, Ballard Power, Infinity Pharmaceuticals, and Credit Acceptance — What Drives Growth in Today's Competitive Landscap
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of KB Home (NYSE:KBH), Fitbit, Inc. (NYSE:FIT), Adamas Pharmaceuticals,...
Mar 12, 2019 04:05 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 56,600 shares of the company’s common stock, at a per...
Mar 04, 2019 04:35 pm ET
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2018, along with key priorities for 2019.  “We are excited to expand GOCOVRI’s impact on...
Feb 20, 2019 04:50 pm ET
Adamas to Present at Two Upcoming Investor Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief...
Feb 20, 2019 04:49 pm ET
Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results on Monday, March 4, 2019, after market close. Subsequently, Adamas’ management team will host a conference...
Feb 08, 2019 06:49 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 50,500 shares of the company’s common stock, at a per...
Feb 07, 2019 08:15 am ET
Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Dev
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Roku, Inc. (NASDAQ:ROKU), AECOM (NYSE:ACM), 1-800 FLOWERS.COM, Inc....
Jan 10, 2019 04:30 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 35,366 shares of the company’s common stock, at a per...
Jan 06, 2019 11:38 am ET
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today outlined key business priorities for 2019 and provided preliminary 2018...
Dec 18, 2018 04:30 pm ET
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that a new patent has been issued that covers GOCOVRI™...
Nov 09, 2018 01:49 pm ET
Adamas to Present at Three November Investor Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Company’s Founder, Chairman and Chief...
Nov 08, 2018 08:30 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Apptio, Adamas Pharmaceuticals, NEXEO SOLUTIONS, Computer Programs and, Solaris Oilfield Infrastructure, and SPX — New Research Emph
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Apptio Inc. (NASDAQ:APTI), Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS),...
Nov 01, 2018 04:01 pm ET
Adamas Reports Third Quarter 2018 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today reported financial results and pipeline updates for the third quarter ended...
Oct 26, 2018 09:00 am ET
Adamas to Announce Third Quarter 2018 Financial Results and Host Conference Call on November 1, 2018
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that it will report third quarter 2018 financial results on Thursday,...
Oct 16, 2018 09:15 am ET
Consolidated Research: 2018 Summary Expectations for Freightcar America, Star Bulk Carriers, Avis Budget Group, Adamas Pharmaceuticals, Model N, and Amphastar Pharmaceuticals — Fundamental Analysis, K
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp....
Oct 08, 2018 08:30 am ET
Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced the presentation of final results from EASE LID 2, the company’s...
Oct 05, 2018 05:51 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option to purchase an aggregate of 49,210 shares of the company’s common stock, at a per...
Oct 04, 2018 09:00 am ET
Adamas Announces Publication of Data Demonstrating Dyskinesia’s Impact on Activities of Daily Living in People with Parkinson’s Disease
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) extended...
Sep 12, 2018 04:30 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 68,251 shares of the company’s common stock, at a per...
Aug 20, 2018 08:25 am ET
Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of In
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor Robotics Ltd. (NASDAQ:MZOR), Kinross Gold Corporation (NYSE:KGC),...
Aug 08, 2018 04:30 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 44,016 shares of the company’s common stock, at a per...
Aug 02, 2018 04:01 pm ET
Adamas Reports Second Quarter 2018 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results and pipeline updates for the second quarter ended June 30, 2018. “We continue to be pleased with the progress of the GOCOVRI launch in its second quarter of...
Aug 01, 2018 09:00 am ET
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the launch of “Dyskinesia Is A Jerk,” an integrated disease education campaign focused on raising awareness about Parkinson’s disease (PD) dyskinesia and its impact, with an educational,...
Jul 26, 2018 12:05 pm ET
Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2018 financial results on Thursday, August 2, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and...
Jul 09, 2018 04:39 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 29,531 shares of the company’s common stock, at a per...
Jun 22, 2018 09:12 am ET
Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release capsules, from the Phase 3 pivotal studies, demonstrating that the reductions in both dyskinesia and OFF...
Jun 08, 2018 05:55 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 37,875 shares of the company’s common stock, at a per...
Jun 07, 2018 04:30 pm ET
Adamas to Present at Two Upcoming Investor Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to present at two upcoming investor conferences: William Blair 38th Annual Growth...
May 24, 2018 09:05 am ET
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release capsules were published online in Clinical Pharmacokinetics. The paper, entitled Pharmacokinetics of ADS-5102...
May 09, 2018 04:05 pm ET
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 19,622 shares of the company’s common stock, at a per...
May 03, 2018 04:05 pm ET
Adamas Reports First Quarter 2018 Financial Results
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported financial results and pipeline updates for the first quarter ended March 31, 2018. “We are pleased with the first quarter of commercialization of GOCOVRI and we are very encouraged by the...
May 02, 2018 03:22 pm ET
Adamas to Present at Two Upcoming Investor Conferences
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences: Gregory T. Went, Ph.D., the company’s Founder, Chairman and Chief Executive Officer, is scheduled to...
Apr 26, 2018 04:05 pm ET
Adamas to Announce First Quarter 2018 Financial Results and Host Conference Call on May 3, 2018
EMERYVILLE, Calif., April 26, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2018 financial results on Thursday, May 3, 2018, after market close. Subsequently, Adamas’ management team will host...
Apr 19, 2018 05:30 am ET
Apr 13, 2018 08:25 am ET
Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora — Research Highlights Growth, Revenue, and Conso
NEW YORK, April 13, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Addus HomeCare Corporation (NASDAQ:ADUS), Adamas Pharmaceuticals,...
Apr 12, 2018 05:09 pm ET
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
EMERYVILLE, Calif., April 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced it will make six data presentations at the 70th Annual Meeting of the American Academy of Neurology (AAN) on April 21-27, 2018 in Los Angeles,...
Apr 03, 2018 09:00 am ET
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
EMERYVILLE, Calif., April 03, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the first patient has been enrolled in its pivotal Phase 3 clinical trial of ADS-5102 (amantadine) extended release capsules in multiple sclerosis (MS)...
Mar 15, 2018 09:00 am ET
Mar 14, 2018 08:25 am ET
Recent Analysis Shows SMART Global, DBV Technologies S.A, ICON, Adamas Pharmaceuticals, Shenandoah Telecommunications, and Costamare Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 14, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SMART Global Holdings, Inc. (NASDAQ:SGH), DBV...
Mar 06, 2018 02:35 pm ET
Adamas to Present at Two Upcoming Investor Conferences
EMERYVILLE, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
Feb 22, 2018 04:01 pm ET
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017
EMERYVILLE, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the fourth quarter and full-year ended December 31, 2017. 
Feb 22, 2018 12:00 pm ET
Adamas Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 22, 2018 / Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) will be discussing their earnings results in their Q4 Earnings Call to be held on February 22, 2018 at 4:30 PM Eastern Time.
Feb 19, 2018 08:01 pm ET
Adamas Announces Declaratory Judgment Action Filed by Osmotica Related to Approved OSMOLEX ER
EMERYVILLE, Calif., Feb. 19, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) announced today that it has learned that Osmotica Pharmaceuticals LLC and Vertical Pharmaceuticals LCC (Osmotica) filed an action in Delaware federal court on February 16, 2018...
Feb 13, 2018 04:01 pm ET
Adamas to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on February 22, 2018
EMERYVILLE, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018 after market close. Subsequently, Adamas’ management...
Feb 09, 2018 05:26 pm ET
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 42,250 shares of...
Feb 08, 2018 09:00 am ET
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate release (IR) who were still experiencing dyskinesia and enrolled into EASE LID 2, the...
Feb 07, 2018 02:09 pm ET
Adamas to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that Gregory T. Went, Ph.D., Founder, Chairman and Chief Executive Officer of Adamas, is scheduled to present at the LEERINK Partners 7th Annual Global...
Feb 01, 2018 04:05 pm ET
Adamas Announces Publication of ADS-5102 Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
--Placebo-controlled proof-of-concept trial demonstrated that ADS-5102 significantly improved walking speed in multiple sclerosis patients with walking impairment--
Jan 29, 2018 08:30 am ET
Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
EMERYVILLE, Calif., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the closing of its previously announced underwritten public offering of its common stock. Adamas sold 3,000,000 shares of its common stock, and the underwriters...
Jan 23, 2018 08:29 pm ET
Adamas Announces Pricing of Public Offering of Common Stock
EMERYVILLE, Calif., Jan. 23, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $41.50 per share....
Jan 22, 2018 04:01 pm ET
Adamas Announces Proposed Public Offering of Common Stock
EMERYVILLE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it plans to offer $85 million of its common stock in an underwritten public offering. Adamas expects to grant the underwriters a 30-day...
Jan 08, 2018 04:41 pm ET
Adamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
EMERYVILLE, Calif., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the full commercial launch of its flagship product, GOCOVRI™ (amantadine) extended release capsules, for the treatment of dyskinesia in patients with Parkinson’s disease receiving...
Dec 08, 2017 04:05 pm ET
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted 64 new employees the option to purchase an aggregate of 77,550 shares of...
Nov 22, 2017 12:42 pm ET
Adamas to Present at Two Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that company management is scheduled to present at two upcoming investor conferences:
Nov 08, 2017 04:17 pm ET
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of the company’s common stock, at a per share exercise price of $27.00, the closing trading price on November 7, 2017, and restricted stock units to acquire 7,650 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Indu...
Nov 08, 2017 04:17 pm ET
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees the option to purchase an aggregate of 15,300 shares of...
Nov 02, 2017 04:01 pm ET
Adamas Reports Recent Achievements and Third Quarter 2017 Financial Results
EMERYVILLE, Calif., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the third quarter ended September 30, 2017.
Nov 01, 2017 10:00 am ET
Kerrisdale Capital Issues Positive Report on Adamas Pharmaceuticals, Inc., and Announces Conference Call Schedule
NEW YORK, Nov. 1, 2017 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a report explaining its long position in Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a ~$500 million company that develops treatments for chronic neurological disorders. Kerrisdale believes that Adamas's drug Gocovri, which is set to hit the market next year, will reach blockbuster status, bringing the fair value of Adamas to more than $100 per share – more than 4x higher than its current price. While critics dismiss Gocovri as a me-too drug, trial data shows that it in fact greatly improv...
Oct 30, 2017 10:31 am ET
Thinking about buying stock in Adamas Pharmaceuticals, Diamond Offshore Drilling, Merck & Company Incorporated, Pfizer Inc, or Under Armour?
CHICAGO, Oct. 30, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADMS, DO, MRK, PFE, and UAA....
Sep 13, 2017 04:53 pm ET
Adamas to Host Investor and Analyst Meeting on September 18, 2017
EMERYVILLE, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that it will host an Investor and Analyst meeting on Monday, September 18, 2017 from 8:00 a.m. – 11:00 a.m. ET in New York, NY. The event will be hosted by members of the Adamas executive management team and will feature presentations from Key Opinion Leaders in the fields of Parkinson’s disease and Multiple sclerosis....
Sep 11, 2017 05:05 pm ET
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees stock options to purchase an aggregate of 15,450 shares of the company’s common stock, at a per share exercise price of $20.77, the closing trading price on September 11, 2017, and restricted stock units to acquire 7,725 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 201...
Aug 24, 2017 04:16 pm ET
Adamas Announces FDA Approval of GOCOVRI™ as First and Only Medication for the Treatment of Dyskinesia in Parkinson’s Disease Patients
EMERYVILLE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the U.S. Food and Drug Administration (FDA) has approved GOCOVRI (amantadine) extended release capsules (previously ADS-5102) for treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI, previously granted orphan drug status by the FDA, is the first and only medicine approved by the FDA for this indication....
Aug 01, 2017 02:33 pm ET
Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017
EMERYVILLE, Calif., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report second quarter 2017 financial results on Tuesday, August 8, 2017 after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update....
Jul 10, 2017 04:32 pm ET
Adamas Reports Inducement Grant to New Chief Financial Officer
EMERYVILLE, Calif., July 10, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Financial Officer, Alfred G. Merriweather. The compensation committee of the company’s board of directors granted Mr. Merriweather a stock option to purchase 112,500 shares of the company’s common stock, at a per share exercise price of $16.98, the closing trading price on July 10, 2017, and restricted stock units to acquire 18,750 shares of the company’s common stock. The stock option and restricted stock units vest over four years a...
Jun 12, 2017 04:01 pm ET
Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology
--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia --...
Jun 08, 2017 04:10 pm ET
Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks
-- New subgroup analyses showed that patients previously treated with amantadine IR received benefit of ADS-5102 comparable to patients previously treated with placebo --...
May 22, 2017 08:30 am ET
Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
-- Phase 1 results show ADS-4101 is better tolerated in healthy volunteers than equivalent doses of VIMPAT® (lacosamide) immediate-release tablets --...
May 09, 2017 04:01 pm ET
Adamas Reports Recent Achievements and First Quarter 2017 Financial Results
EMERYVILLE, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported recent achievements and financial results for the first quarter ended March 31, 2017....
May 05, 2017 05:42 pm ET
Adamas Reports Inducement Grant to New Chief Operating Officer
EMERYVILLE, Calif., May 05, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today reported the grant of inducement awards to its new Chief Operating Officer, Richard A. King. The compensation committee of the company’s board of directors granted Mr. King a stock option to purchase 168,750 shares of the company’s common stock, at a per share exercise price of $17.40, the closing trading price on May 5, 2017, and restricted stock units to acquire 28,125 shares of the company’s common stock. The stock option and restricted stock units vest over four years and were granted pu...
May 02, 2017 04:06 pm ET
Adamas to Announce First Quarter 2017 Financial Results and Host Conference Call on May 9, 2017
EMERYVILLE, Calif., May 02, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that the company will report first quarter 2017 financial results on Tuesday, May 9, 2017 after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.